Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 11, 2021
https://www.tandfonline.com/toc/khvi20/current

 

Article
Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis
Tosin Yinka Akintunde, Taha Hussein Musa, Hassan Hussein Musa, Shaojun Chen, Elhakim Ibrahim, Sayibu Muhideen & Joseph Kawuki
Pages: 4246-4258
Published online: 16 Jul 2021

Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 11, 2021
https://www.tandfonline.com/toc/khvi20/current

 

review article
Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review
Chiara Cadeddu, Carolina Castagna, Martina Sapienza, Teresa Eleonora Lanza, Rosaria Messina, Manuela Chiavarini, Walter Ricciardi & Chiara de Waure
Pages: 4470-4486
Published online: 02 Sep 2021

Feasibility, acceptability, and effectiveness of non-pharmaceutical interventions against infectious diseases among crisis-affected populations: a scoping review

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 29 Jan 2022]

 

Feasibility, acceptability, and effectiveness of non-pharmaceutical interventions against infectious diseases among crisis-affected populations: a scoping review
Non-pharmaceutical interventions (NPIs) are a crucial suite of measures to prevent and control infectious disease outbreaks. Despite being particularly important for crisis-affected populations and those livin…
Authors: Jonathan A. Polonsky, Sangeeta Bhatia, Keith Fraser, Arran Hamlet, Janetta Skarp, Isaac J. Stopard, Stéphane Hugonnet, Laurent Kaiser, Christian Lengeler, Karl Blanchet and Paul Spiegel
Citation: Infectious Diseases of Poverty 2022 11:14
Content type: Scoping Review
Published on: 28 January 2022

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

JAMA
January 25, 2022, Vol 327, No. 4, Pages 305-401
https://jamanetwork.com/journals/jama/currentissue

 

Original Investigation
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
Matthew E. Oster, MD, MPH; David K. Shay, MD, MPH; John R. Su, MD, PhD, MPH; et al.
free access has active quiz
JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110
This descriptive study compares the effect of mRNA-based COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) vs mRNA-1273 (Moderna) on the reported cases of myocarditis in the US after each vaccination dose.

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

JAMA
January 25, 2022, Vol 327, No. 4, Pages 305-401
https://jamanetwork.com/journals/jama/currentissue

 

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel
Avishay Spitzer, MD; Yoel Angel, MD, MBA; Or Marudi, MSc; et al.
free access has active quiz
JAMA. 2022;327(4):341-349. doi:10.1001/jama.2021.23641
This cohort study estimates the association of a BNT162b2 (Pfizer-BioNTech) vaccine booster dose with SARS-CoV-2 infections among health care workers in Israel previously vaccinated with a 2-dose series of BNT162b2.

Winter of Omicron—The Evolving COVID-19 Pandemic

JAMA
January 25, 2022, Vol 327, No. 4, Pages 305-401
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Winter of Omicron—The Evolving COVID-19 Pandemic
Carlos del Rio, MD; Saad B. Omer, MBBS, MPH, PhD; Preeti N. Malani, MD, MSJ
free access has multimedia has audio
JAMA. 2022;327(4):319-320. doi:10.1001/jama.2021.24315
This Viewpoint discusses the Omicron variant of SARS-CoV-2, including its likely origin, the importance of vaccination, the other tools available to combat a surge in COVID-19 cases, and the possibility of a “twindemic” with influenza.

Identifying COVID-19 and H1N1 vaccination hesitancy or refusal among health care providers across North America, the United Kingdom, Europe, and Australia: a scoping review protocol

JBI Evidence Synthesis
January 2022 – Volume 20 – Issue 1
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

 

SYSTEMATIC REVIEW PROTOCOLS
Identifying COVID-19 and H1N1 vaccination hesitancy or refusal among health care providers across North America, the United Kingdom, Europe, and Australia: a scoping review protocol
Gallant, Allyson J.; Steenbeek, Audrey; Curran, Janet A.
JBI Evidence Synthesis. 20(1):173-180, January 2022.

Parental experiences of caring for their preschool children after declining vaccines: a qualitative systematic review protocol

JBI Evidence Synthesis
January 2022 – Volume 20 – Issue 1
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

 

Parental experiences of caring for their preschool children after declining vaccines: a qualitative systematic review protocol
Huel, Christine; Harding, Jillian; MacKinnon, Karen; More
JBI Evidence Synthesis. 20(1):196-203, January 2022.

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Journal of Infectious Diseases
Volume 225, Issue 1, 1 January 2022
https://academic.oup.com/jid/issue/225/1

 

MAJOR ARTICLES AND BRIEF REPORTS
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
Yaki Saciuk, Jennifer Kertes, Naama Shamir Stein, Anat Ekka Zohar
The Journal of Infectious Diseases, Volume 225, Issue 1, 1 January 2022, Pages 30–33, https://doi.org/10.1093/infdis/jiab556
Providing a third dose of BNT152b2 6 months after the first 2 doses evidenced a vaccine effectiveness against infection rate of 89%. The reduction in infection risk 2 months after the third-dose vaccination campaign reinforces the wisdom of its implementation.

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

The Lancet
Jan 29, 2022 Volume 399 Number 10323 p411-494, e2
https://www.thelancet.com/journals/lancet/issue/current

 

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
Lulu Bravo, et al.

Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability

The Lancet
Jan 29, 2022 Volume 399 Number 10323 p411-494, e2
https://www.thelancet.com/journals/lancet/issue/current

 

Health Policy
Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability
Suerie Moon, PhD Jana Armstrong, MBA Brian Hutler, PhD Prof Ross Upshur, MD Rachel Katz, MA Caesar Atuire, PhD et al. Show all authors
Published:December 10, 2021
DOI: https://doi.org/10.1016/S0140-6736(21)02344-8
Summary
The Access to COVID-19 Tools Accelerator (ACT-A) is a multistakeholder initiative quickly constructed in the early months of the COVID-19 pandemic to respond to a catastrophic breakdown in global cooperation. ACT-A is now the largest international effort to achieve equitable access to COVID-19 health technologies, and its governance is a matter of broad public importance. We traced the evolution of ACT-A’s governance through publicly available documents and analysed it against three principles embedded in the founding mission statement of ACT-A: participation, transparency, and accountability. We found three challenges to realising these principles. First, the roles of the various organisations in ACT-A decision making are unclear, obscuring who might be accountable to whom and for what. Second, the absence of a clearly defined decision making body; ACT-A instead has multiple centres of legally binding decision making and uneven arrangements for information transparency, inhibiting meaningful participation. Third, the nearly indiscernible role of governments in ACT-A, raising key questions about political legitimacy and channels for public accountability. With global public health and billions in public funding at stake, short-term improvements to governance arrangements can and should now be made. Efforts to strengthen pandemic preparedness for the future require attention to ethical, legitimate arrangements for governance.

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Nature
Volume 601 Issue 7894, 27 January 2022
https://www.nature.com/nature/volumes/601/issues/7894

 

Article | 23 November 2021 | Open Access
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.
Jonas S. Heitmann, Tatjana Bilich, Juliane S. Walz

The past, present and future of Registered Reports

Nature Human Behaviour
Volume 6 Issue 1, January 2022
https://www.nature.com/nathumbehav/volumes/6/issues/1

 

Review Article | 15 November 2021
The past, present and future of Registered Reports
Registered Reports were introduced a decade ago as a means for improving the rigour and credibility of confirmatory research. Chambers and Tzavella overview the format’s past, its current status and future developments.
Christopher D. Chambers, Loukia Tzavella

The future of human behaviour research

Nature Human Behaviour
Volume 6 Issue 1, January 2022
https://www.nature.com/nathumbehav/volumes/6/issues/1

 

Feature | 27 January 2022
The future of human behaviour research
Human behaviour is complex and multifaceted, and is studied by a broad range of disciplines across the social and natural sciences. To mark our 5th anniversary, we asked leading scientists in some of the key disciplines that we cover to share their vision of the future of research in their disciplines. Our contributors underscore how important it is to broaden the scope of their disciplines to increase ecological validity and diversity of representation, in order to address pressing societal challenges that range from new technologies, modes of interaction and sociopolitical upheaval to disease, poverty, hunger, inequality and climate change. Taken together, these contributions highlight how achieving progress in each discipline will require incorporating insights and methods from others, breaking down disciplinary silos.
Janet M. Box-Steffensmeier, Jean Burgess, Claudia Wagner

Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever

Nature Medicine
Volume 28 Issue 1, January 2022
https://www.nature.com/nm/volumes/28/issues/1

 

News Feature | 14 January 2022
Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever
Medical discoveries have been shared at an unprecedented pace during the COVID-19 pandemic, but so have fraudulent studies, which has led to worries about scientific integrity.
Clare Watson

Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 29 Jan 2022)

 

Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries
Roy Rillera Marzo, Absar Ahmad, Md. Saiful Islam, Mohammad Yasir Essar, Petra Heidler, Isabel King, Arulmani Thiyagarajan, Kittisak Jermsittiparsert, Karnjana Songwathana, Delan Ameen Younus, Radwa Abdullah El-Abasiri, Burcu Kucuk Bicer, Nhat Tan Pham, Titik Respati, Susan Fitriyana, Erwin Martinez Faller, Aries Moralidad Baldonado, Md Arif Billah, Yadanar Aung, Shehu Muhammad Hassan, Muhammad Mujtaba Asad, Kareem Ahmed El-Fass, Sudip Bhattacharya, Sunil Shrestha, Nouran Ameen Elsayed Hamza, Pascal Friedmann, Michael Head, Yulan Lin, Siyan Yi
Research Article | published 28 Jan 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0010103

Defining clinical trial quality from the perspective of resource-limited settings: A qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 29 Jan 2022)

 

Defining clinical trial quality from the perspective of resource-limited settings: A qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa
Angela De Pretto-Lazarova, Claudia Fuchs, Peter van Eeuwijk, Christian Burri
Research Article | published 27 Jan 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0010121

Assessment of vaccination timeliness and associated factors among children in Toke Kutaye district, central Ethiopia: A Mixed study

PLoS One
http://www.plosone.org/
[Accessed 29 Jan 2022]

 

Research Article
Assessment of vaccination timeliness and associated factors among children in Toke Kutaye district, central Ethiopia: A Mixed study
Kuma Dirirsa, Mulugeta Makuria, Ermias Mulu, Berhanu Senbeta Deriba
Research Article | published 27 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0262320

Determinants of maternal influenza vaccination in the context of low- and middle-income countries: A systematic review

PLoS One
http://www.plosone.org/
[Accessed 29 Jan 2022]

 

Determinants of maternal influenza vaccination in the context of low- and middle-income countries: A systematic review
Shrish Raut, Aditi Apte, Manikandan Srinivasan, Nonita Dudeja, Girish Dayma, Bireshwar Sinha, Ashish Bavdekar
Research Article | published 26 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0262871

COVID-19 vaccination beliefs, attitudes, and behaviours among health and social care workers in the UK: A mixed-methods study

PLoS One
http://www.plosone.org/
[Accessed 29 Jan 2022]

 

COVID-19 vaccination beliefs, attitudes, and behaviours among health and social care workers in the UK: A mixed-methods study
Sadie Bell, Richard M. Clarke, Sharif A. Ismail, Oyinkansola Ojo-Aromokudu, Habib Naqvi, Yvonne Coghill, Helen Donovan, Louise Letley, Pauline Paterson, Sandra Mounier-Jack
Research Article | published 24 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0260949

One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review

Vaccine
Volume 40, Issue 2 Pages 173-396 (21 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/2

 

Review article Open access
One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review
Anar Andani, Pierre van Damme, Eveline M. Bunge, Fernanda Salgado, … Bernard Hoet
Pages 196-205

Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation

Vaccine
Volume 40, Issue 2 Pages 173-396 (21 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/2

 

Research article Full text access
Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation
Michael V. Bronstein, Erich Kummerfeld, Angus MacDonald, Sophia Vinogradov
Pages 213-222

Epidemiology of pertussis in Costa Rica and the impact of vaccination: A 58-year experience (1961–2018)

Vaccine
Volume 40, Issue 2 Pages 173-396 (21 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/2

 

Research article Open access
Epidemiology of pertussis in Costa Rica and the impact of vaccination: A 58-year experience (1961–2018)
María L. Avila-Agüero, Kattia Camacho-Badilla, Rolando Ulloa-Gutierrez, Carlos Espinal-Tejada, … James D. Cherry
Pages 223-228

The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study

Vaccine
Volume 40, Issue 2 Pages 173-396 (21 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/2

 

Research article Open access
The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study
Carlotta Fack, Robin Wood, Mark Hatherill, Frank Cobelens, Sabine Hermans
Pages 364-369

National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study

Vaccine
Volume 40, Issue 2 Pages 173-396 (21 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/2

 

Research article Open access
National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study
Jessica Price, Jessica Mooney, Carolyn Bain, John Tanko Bawa, … William P. Hausdorff
Pages 370-379

Pre-Print Servers

Pre-Print Servers

 

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 29 Jan 2022]

[No new digest content identified]

 

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…

Comparative effectiveness of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign
Theodore Lytras, Flora Kontopidou, Angeliki Lambrou, Sotirios Tsiodras
medRxiv 2022.01.28.22270009; doi: https://doi.org/10.1101/2022.01.28.22270009

Critical success factors for high routine immunization performance: A case study of Nepal
Kyra A Hester, Zoe Sakas, Anna S Ellis, Anindya Sekhar Bose, Roopa Darwar, Jhalak Gautam, Chandni Jaishwal, Hanleigh James, Pinar Keskinocak, Dima Nazzal, Emily Ogutu, Katie Rodriguez, Francisco Castillo Zunino, Sameer Dixit, Robert A. Bednarczyk, Matthew C Freeman, Vaccine Exemplars Research Consortium
medRxiv 2022.01.28.22270023; doi: https://doi.org/10.1101/2022.01.28.22270023

Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations
Brittany A Petros, Jacquelyn Turcinovic, Nicole Welch, Laura White, Eric Kolaczyk, Matthew Bauer, Michael Cleary, Sabrina Dobbins, Lynn Doucette-Stamm, Mitch Gore, Parvathy Nair, Tien Nguyen, Scott Rose, Bradford Taylor, Daniel Tsang, Erik Wendlandt, Michele Hope, Judy Platt, Karen Jacobson, Tara Bouton, Seyho Yune, Jared Auclair, Lena Landaverde, Catherine M. Klapperich, Davidson H Hamer, William P Hanage, Bronwyn MacInnis, Pardis Sabeti, John H Connor, Michael Springer
medRxiv 2022.01.27.22269787; doi: https://doi.org/10.1101/2022.01.27.22269787

Estimates of the impact on COVID-19 deaths of unequal global allocations of vaccines
John Paul Callan
medRxiv 2022.01.26.22269347; doi: https://doi.org/10.1101/2022.01.26.22269347

Is mandatory vaccination in population over 60 adequate to control the COVID-19 pandemic in E.U.?
Nikolaos Rachaniotis, Thomas Dasaklis, Filippos Fotopoulos, Michael Chouzouris, Thomas Georgiadis, Antigoni Lyberaki, Platon Tinios
medRxiv 2022.01.25.22269867; doi: https://doi.org/10.1101/2022.01.25.22269867

Critical success factors for high routine immunization performance: A case study of Senegal
Zoe Sakas, Kyra A. Hester, Katie Rodriguez, Saly Amos Diatta, Anna S. Ellis, Daouda Malick Gueye, Dawn Matapano, Pr Souleymane Mboup, Emily Awino Ogutu, Chenmua Yang, Robert A. Bednarczyk, Matthew C Freeman, Moussa Sarr, Vaccine Exemplars Research Consortium
medRxiv 2022.01.25.22269847; doi: https://doi.org/10.1101/2022.01.25.22269847

Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant
Khadija Khan, Farina Karim, Sandile Cele, James Emmanuel San, Gila Lustig, Houriiyah Tegally, Yuval Rosenberg, Mallory Bernstein, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Nokuthula Ngcobo, Yoliswa Miya, Matilda Mazibuko, Ntombifuthi Mthabela, Zoey Mhlane, Nikiwe Mbatha, Jennifer Giandhari, Yajna Ramphal, Taryn Naidoo, Nithendra Manickchund, Nombulelo Magula, Salim Abdool Karim, Glenda Gray, Willem Hanekom, Anne von Gottberg, Ron Milo, Bernadett Gosnell, Richard Lessells, Tulio de Oliveira, Penny Moore, Yunus S Moosa, Alex Sigal
medRxiv 2021.12.27.21268439; doi: https://doi.org/10.1101/2021.12.27.21268439

COVID-19 vaccine attitude and its predictors among people living with chronic health conditions in Ibadan, Nigeria
Lucia Yetunde Ojewale, Rotimi Felix Afolabi, Adesola Ogunniyi
medRxiv 2022.01.27.22269947; doi: https://doi.org/10.1101/2022.01.27.22269947

The impacts of increased global vaccine sharing on the COVID-19 pandemic; a retrospective modelling study
Sam Moore, Edward M Hill, Louise J Dyson, Michael J Tildesley, Matt J Keeling
medRxiv 2022.01.26.22269877; doi: https://doi.org/10.1101/2022.01.26.22269877

Systematic review of social determinants of childhood immunisation in low- and middle-income countries and equity impact analysis of childhood vaccination coverage in Nigeria
Sarah V Williams, Tanimola Akande, Kaja Abbas
medRxiv 2022.01.24.22269771; doi: https://doi.org/10.1101/2022.01.24.22269771

South African Population Immunity and Severe Covid-19 with Omicron Variant
Shabir Madhi, Gaurav Kwatra, Jonathan E Myers, Waasila Jassat, Nisha Dhar, Christian K Mukendi, Amit Nana, Lucille Blumberg, Richard Welch, Nicoletta Ngorima-Mabhena, Portia C Mutevedzi
medRxiv 2021.12.20.21268096; doi: https://doi.org/10.1101/2021.12.20.21268096

Trust in the scientific research community predicts intent to comply with COVID-19 prevention measures: An analysis of a large-scale international survey dataset
Hyemin Han
medRxiv 2021.12.08.21267486; doi: https://doi.org/10.1101/2021.12.08.21267486

Wellcome Open Research [to 29 Jan 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 29 Jan 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.
Research Article metrics
Revised
A patient satisfaction survey and educational package to improve the care of people hospitalised with COVID-19: a quality improvement project, Liverpool, UK [version 2; peer review: 2 approved]
Muhammad Shamsher Ahmad, Scott Rory Hicks, Rebecca Watson, Rajia Akter Ahmed, Lewis Jones, Marcella Vaselli, Meng-San Wu, Fatima Hayat, Libuse Ratcliffe, Mark McKenna, Paul Hine, Sylviane Defres, Tom Wingfield
Peer Reviewers Katherine Ajdukiewicz; Vishesh Paul
Funder
Wellcome Trust
LATEST VERSION PUBLISHED 25 Jan 2022

Systematic Review metrics AWAITING PEER REVIEW
The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. [version 1; peer review: awaiting peer review]
Alistair R.D. McLean, Sumayyah Rashan, Lien Tran, Lorenzo Arena, AbdulAzeez Lawal, Brittany J. Maguire, Sandra Adele, Emilia Sitsofe Antonio, Matthew Brack, Fiona Caldwell, Verena Ilona Carrara, Reema Charles, Barbara Wanjiru Citarella, Terrence B. Epie, Vitalis Fambombi Feteh, Kalynn Kennon, Gerald Jamberi Makuka, Roland Ngu, Amen-Patrick Nwosu, Sopuruchukwu Obiesie, Chinwe Ogbonnaa-Njoku, Parvesh Paul, Caitlin Richmond, Sauman Singh-Phulgenda, Samantha Strudwick, Carina S.B. Tyrrell, Kasia Stepniewska, Nathalie Strub-Wourgaft, Nicholas J. White, Philippe J. Guérin
Peer Reviewers Invited
Funders
Wellcome
Bundesministerium für Bildung und Forschung, Germany
International Solidarity Service, Republic and Canton of Geneva
PUBLISHED 25 Jan 2022
Abstract
Background: Many available medicines have been evaluated as potential repurposed treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study landscape for 32 priority pharmacological treatments identified following consultation with external experts of the COVID-19 Clinical Research Coalition.
Methods: All eligible trial registry records identified by systematic searches of the World Health Organisation International Clinical Trials Registry Platform as of 26th May 2021 were reviewed and extracted. A descriptive summary of study characteristics was performed.
Results: We identified 1,314 registered studies that included at least one of the 32 priority pharmacological interventions. The majority (1,043, 79%) were randomised controlled trials (RCTs). The sample size of the RCTs identified was typically small (median (25th, 75th percentile) sample size = 140 patients (70, 383)), i.e. individually powered only to show very large effects. The most extensively evaluated medicine was hydroxychloroquine (418 registered studies). Other widely studied interventions were convalescent plasma (n=208), ritonavir (n=189) usually combined with lopinavir (n=181), and azithromycin (n=147). Very few RCTs planned to recruit participants in low-income countries (n=14; 1.3%). A minority of studies (348, 26%) indicated a willingness to share individual participant data. The living systematic review data are available at https://iddo.cognitive.city
Conclusions: There are many registered studies planning to evaluate available medicines as potential repurposed treatments of COVID-19. Most of these planned studies are small, and therefore substantially underpowered for most relevant endpoints. Very few are large enough to have any chance of providing enough convincing evidence to change policies and practices. The sharing of individual participant data (IPD) from these studies would allow pooled IPD meta-analyses which could generate definitive conclusions, but most registered studies did not indicate that they were willing to share their data.

Think Tanks

Think Tanks
 
 
Brookings [to 29 Jan 2022]
http://www.brookings.edu/
Accessed 29 Jan 2022
Coronavirus (COVID-19)
When a universal coronavirus vaccine arrives, we should test payments for vaccine recipients
Robert E. Litan
Wednesday, January 26, 2022

Africa in Focus
Vaccine inequity: Ensuring Africa is not left out
Michel Sidibé
Monday, January 24, 2022
 
 
Chatham House [to 29 Jan 2022]
https://www.chathamhouse.org/
Accessed 29 Jan 2022
[No new digest content identified]

 
 
CSIS
https://www.csis.org/
Accessed 29 Jan 2022
Upcoming Event
Covid-19 Vaccine Confidence at One Year
February 4, 2022

Podcast Episode
Dr. Michael Osterholm: “Don’t Be Surprised When You Are Surprised.”
January 28, 2022 | By H. Andrew Schwartz, J. Stephen Morrison

Report
Innovative Data Collection Methods for International Development
January 26, 2022 | By Daniel F. Runde, Romina Bandura

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 29 Jan 2022
January 28, 2022 News Release
42% of Adults, and 70% of Those Likely Booster-Eligible, Now Say They’ve Gotten a COVID-19 Booster Shot; The Share Who Received At Least One Dose Inches Up to 77% in Omicron’s Wake
Black and Hispanic Adults are More Likely Than White Adults to Worry About Omicron’s Effects, Including Becoming Seriously Ill or Missing Work Due to Infection The latest KFF COVID-19 Vaccine Monitor report shows that 42% of all adults nationwide have received a COVID-19 booster and more than three quarters (77%)…

January 26, 2022 News Release
Key Facts on Health and Health Care by Race and Ethnicity
With the COVID-19 pandemic impacting communities of color disproportionately in their health and economic well-being, long-term racial and ethnic disparities have received growing attention. But these inequities in our health system are not new and are a part of larger issues of systemic racism. An updated KFF chart pack analyzes…